ClinicalTrials.gg
CompletedNCT06677164Updated Oct 13, 2026

Gluteus Maximus Strengthening Exercises Augmented by High-Intensity Laser Therapy in Patients With Plantar Fasciopathy

An interventional study of Gluteus Maximus strengthening exercise and high-intensity laser therapy in Plantar Fascia, sponsored by Deraya University. Completed at 1 site in Egypt. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Deraya University · Not applicable, Interventional, and Treatment

How we know

Updated Oct 13, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 138 studies in Obesity with a site in Egypt — 32 open to participants now, 39 under way, none of them phase 3. Obesity · Egypt.

Enrollment
24th of 102
100 · median 60
Started
2024
with 18 others
No phase
90 of 138
21 open now
Registered
85th of 138
by date

Among the 138 studies in Obesity with a site in Egypt, this one is the 24th largest by enrollment of the 102 interventional ones that give a count, is one of 19 that started in 2024, is one of 90 with no phase, and was the 85th registered.

Obesity

11,560 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

32 of the 138 studies in Obesity with a site in Egypt are open now. Recruiting first, the newest first:

27 more — sign in →

All 32 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 138 studies in Obesity with a site in Egypt, or all of them as a file.
02

Study summary

Plantar heel pain is one of the most commonly encountered problems of the feet in adults [1]. It accounts for nearly 11%-15% of all foot symptoms, The purpose of this study was to investigate the effectiveness of high intensity laser therapy combined with gluteus Maximus strengthening exercise on pain, thickness of plantar fascia, and function of the foot.

03

Conditions studied

  • Plantar Fascia

Browse trials for

Keywords

  • Plantar heel pain
  • obese
  • laser therapy
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Unilateral plantar heel pain with or without calcaneal spur for more than 3 months.
  • Tenderness at the insertion of the plantar fascia
  • index will be from 25 up to 30
  • Patient will wear silicone insole .
  • Diagnosis of PF based on orthopedic referral

Exclusion criteria

Exclusion Criteria:

  • Patients with presence of foot deformity,
  • systemic inflammatory arthritis disease,
  • foot surgery, or
  • plantar heel pain due to trauma,
  • wound, or infection in the foot,
  • received oral
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Experimental: High intensity laser therapy combined with Gluteus Maximus strengthening exercise

    patients will receive High intensity laser therapy combined with Gluteus Maximus strengthening exercise

    Procedure: Gluteus Maximus strengthening exercise · Device: high-intensity laser therapy

  • Active comparator
    Active Comparator: High intensity laser therapy

    patients will receive High intensity laser therapy.

    Device: high-intensity laser therapy

Interventions

  • ProcedureGluteus Maximus strengthening exercise

    Maximus strengthening exercise for eight weeks using weight progression tools either elastic band or sand weight by assuming two modes of exercises (clamshell exercise, prone hip extension) with stretching exercise (hamstring, gastrocnemius, soleus, and plantar fascia) 2 sessions per week for 8 weeks

  • Devicehigh-intensity laser therapy

    A 3-phase treatment program will be performed in each session on the plantar fascia area. Treatment of trigger points in phase 1 and 2 by using power of 9 watts, E2C mode for 6 minute of 2 phases. The draining and vascularization-promoting application involve the whole foot sole, starting from the heel area in phase three by using power of 9 watts, CW mode with energy of 100J/cm2.

06

What researchers measure

Primary outcomes

  1. Pain assessment

    Pressure algometry (kg/cm2). Pressure algometry will be performed on both affected and healthy feet

    Time frame: 3 months

  2. Plantar fascia thickness

    by using Ultrasonography, in a longitudinal view of the tendon in both affected and healthy feet (mm). the normal plantar fascia thickness is less than 4 mm

    Time frame: 3 months

07

Study locations

1 site
  • Deraya university
    Minya, 05673, Egypt
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2024 to primary completion in Feb 2025, 3 months.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's 3 months is below that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: start Mar 2024 → Nov 2024, primary completion Nov 2024 → Feb 2025 and completion Dec 2024 → Mar 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2024
First posted
Nov 6, 2024
StartActual
Nov 20, 2024was Mar 2024
Primary completionActual
Feb 22, 2025was Nov 2024
CompletionActual
Mar 1, 2025was Dec 2024
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Mar 10, 2024→Nov 20, 2024
Oct 13, 2026
Primary completion
Nov 22, 2024→Feb 22, 2025
Oct 13, 2026
Study completion
Dec 1, 2024→Mar 1, 2025
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Start date Mar 10, 2024→Nov 20, 2024
    Primary completion Nov 22, 2024→Feb 22, 2025
    Study completion Dec 1, 2024→Mar 1, 2025
    + 3 other changes: verification date, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06677164
Lead sponsor
Deraya University
Responsible party
Soad Ali (associate professor, Deraya University) — Principal investigator
First posted
Nov 6, 2024
Start date
Nov 20, 2024
Primary completion
Feb 22, 2025
Completion
Mar 1, 2025
Last update
Oct 13, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion